Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evelo Biosciences, Inc.EVLO · Entity 108468 | Director | June 17, 2020 | June 18, 2020 |
| Generate Biomedicines, Inc.GENB · Entity 1553 | Director | February 26, 2026 | March 02, 2026 |
| Syros Pharmaceuticals, Inc.SYRS · Entity 85437 | Director | December 02, 2024 | December 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evelo Biosciences, Inc.
Report date June 17, 2020 · Filed June 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.59 · Expires 2030-06-17 | Direct | 15,690 |
Reported balance
After 2020-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-17 · Grant · Acquired 15,690 · Balance 15,690 F1: The option vests on the earlier of June 17, 2021 or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Issuer's board of directors as a non-employee director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of June 17, 2021 or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Issuer's board of directors as a non-employee director through such vesting date.
Generate Biomedicines, Inc.
Report date February 26, 2026 · Filed March 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-02-25 | Direct | 29,561 |
Reported balance
After 2026-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 29,561 · Balance 29,561 F1: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.
Syros Pharmaceuticals, Inc.
Report date December 02, 2024 · Filed December 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,000 |
Reported balance
After 2024-12-02 transaction · row 1
1 source rowRow 1 · 2024-12-02 · Sale · Disposed 37,070 · Balance 4,000 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.2680 to $0.2726, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.2680 to $0.2726, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Seagen Inc.
Report date December 14, 2023 · Filed December 15, 2023
Section 16 reporting ended · disclosed 2023-12-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 1
1 source rowRow 1 · 2023-12-14 · Disposition to issuer · Disposed 62,753 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration"). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.25 · Expires 2024-05-16 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-12-14 · Disposition to issuer · Disposed 8,750 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.94 · Expires 2025-05-15 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-12-14 · Disposition to issuer · Disposed 9,260 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.82 · Expires 2026-05-20 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-12-14 · Disposition to issuer · Disposed 9,260 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.60 · Expires 2027-05-19 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-12-14 · Disposition to issuer · Disposed 9,260 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.77 · Expires 2028-05-18 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-12-14 · Disposition to issuer · Disposed 9,260 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.38 · Expires 2029-05-20 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-12-14 · Disposition to issuer · Disposed 7,038 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $160.33 · Expires 2030-05-15 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-12-14 · Disposition to issuer · Disposed 3,171 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $147.50 · Expires 2031-05-14 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-12-14 · Disposition to issuer · Disposed 3,462 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $135.63 · Expires 2032-05-13 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-12-14 · Disposition to issuer · Disposed 3,676 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-12-14 · Disposition to issuer · Disposed 2,044 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").
F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration").
F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2021 Filed Feb 19, 2021 16:10 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 304,000 | $0.00 Strike: $11.41 | $0.00 |
DisclosureSEC source: 0001209191-21-012331 · doc4.xml · derivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,000 Underlying: Common Stock · 304,000 shares Expires 2031-02-16 F1 · derivative.exercise_date: This option becomes exercisable as to one quarter (1/4th) of the shares on February 28, 2022, with the remainder vesting in monthly installments equal to one forty-eighth (1/48th) of the original number of shares at the end of each of the next thirty-six (36) months thereafter. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 16:58 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionStock Option (right to buy) · Derivative | 4,988 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0001209191-20-064667 · doc4.xml · derivative · entry 6 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,012 Underlying: Common Stock · 4,988 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option to purchase 285,000 shares became exercisable as to 25% of the shares underlying the award on February 28, 2019, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award at the end of each successive month thereafter. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 16:58 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionStock Option (right to buy) · Derivative | 14,168 | $0.00 Strike: $8.51 | $0.00 |
DisclosureSEC source: 0001209191-20-064667 · doc4.xml · derivative · entry 5 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,165 Underlying: Common Stock · 14,168 shares Expires 2026-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 16:58 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionStock Option (right to buy) · Derivative | 10,761 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001209191-20-064667 · doc4.xml · derivative · entry 4 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,524 Underlying: Common Stock · 10,761 shares Expires 2025-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 16:58 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionCommon Stock | 4,988 | $10.09 | $50,328.92 |
DisclosureSEC source: 0001209191-20-064667 · doc4.xml · nonDerivative · entry 3 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 563,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 16:58 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionCommon Stock | 14,168 | $8.51 | $120,569.68 |
DisclosureSEC source: 0001209191-20-064667 · doc4.xml · nonDerivative · entry 2 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 558,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 16:58 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionCommon Stock | 10,761 | $3.04 | $32,713.44 |
DisclosureSEC source: 0001209191-20-064667 · doc4.xml · nonDerivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 17:14 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option (Right to Buy) · Derivative | 15,690 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001694665-20-000058 · wf-form4_159251484038936.xml · derivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,690 Underlying: Common Stock · 15,690 shares Expires 2030-06-17 F1 · derivative.exercise_date: The option vests on the earlier of June 17, 2021 or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Issuer's board of directors as a non-employee director through such vesting date. Read SEC document |
| May 15, 2020 Filed May 19, 2020 19:11 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,171 | $0.00 Strike: $160.33 | $0.00 |
DisclosureSEC source: 0001203311-20-000051 · edgardoc.xml · derivative · entry 2 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,171 Underlying: Common Stock · 3,171 shares Expires 2030-05-15 Read SEC document |
| May 15, 2020 Filed May 19, 2020 19:11 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 1,335 | $0.00 | $0.00 |
DisclosureSEC source: 0001203311-20-000051 · edgardoc.xml · nonDerivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,098 F1 · security: These restricted stock units will be settled in common stock upon vesting. F2 · date: These restricted stock units shall vest in full on May 15, 2021. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 16:04 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 294,000 | $0.00 Strike: $7.54 | $0.00 |
DisclosureSEC source: 0001209191-20-009591 · doc4.xml · derivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,000 Underlying: Common Stock · 294,000 shares Expires 2030-02-12 F1 · derivative.exercise_date: This option becomes exercisable as to 25% of the shares on February 28, 2021, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award at the end of each successive month thereafter. Read SEC document |
| December 23, 2019 Filed Dec 23, 2019 16:54 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionStock Option (right to buy) · Derivative | 8,210 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001209191-19-061818 · doc4.xml · derivative · entry 4 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,018,123 Underlying: Common Stock · 8,210 shares Expires 2025-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 23, 2019 Filed Dec 23, 2019 16:54 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionStock Option (right to buy) · Derivative | 10,762 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001209191-19-061818 · doc4.xml · derivative · entry 3 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,026,333 Underlying: Common Stock · 10,762 shares Expires 2025-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on June 9, 2015 and vests upon the achievement of performance-based criteria, and in any event will vest in full on June 9, 2021, subject to continued service. Read SEC document |
| December 23, 2019 Filed Dec 23, 2019 16:54 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionStock Option (right to buy) · Derivative | 33,429 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001209191-19-061818 · doc4.xml · derivative · entry 2 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,037,095 Underlying: Common Stock · 33,429 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 23, 2019 Filed Dec 23, 2019 16:54 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionCommon Stock | 52,401 | $3.04 | $159,299.04 |
DisclosureSEC source: 0001209191-19-061818 · doc4.xml · nonDerivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 533,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 08:28 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option (Right to Buy) · Derivative | 15,690 | $0.00 Strike: $7.07 | $0.00 |
DisclosureSEC source: 0001694665-19-000041 · wf-form4_156042887728247.xml · derivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,690 Underlying: Common Stock · 15,690 shares Expires 2029-06-12 F1 · derivative.exercise_date: Option vests on the earlier of June 12, 2020 or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Issuer's board of directors as a non-employee director through each such vesting date. Read SEC document |
| May 20, 2019 Filed May 22, 2019 21:44 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,038 | $0.00 Strike: $64.38 | $0.00 |
DisclosureSEC source: 0000899243-19-014440 · doc4.xml · derivative · entry 2 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,038 Underlying: Common Stock · 7,038 shares Expires 2029-05-20 F3 · derivative.exercise_date: These options shall vest in full on May 20, 2020. Read SEC document |
| May 20, 2019 Filed May 22, 2019 21:44 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 2,963 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-014440 · doc4.xml · nonDerivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,763 F1 · security: These restricted stock units will be settled in common stock upon vesting. F2 · date: These restricted stock units shall vest in full on May 20, 2020. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 17:19 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 285,000 | $0.00 Strike: $6.71 | $0.00 |
DisclosureSEC source: 0001209191-19-010287 · doc4.xml · derivative · entry 2 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,000 Underlying: Common Stock · 285,000 shares Expires 2029-02-11 F2 · derivative.exercise_date: This option becomes exercisable as to 25% of the shares underlying the award on February 29, 2020, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award at the end of each successive month thereafter. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 17:19 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantCommon Stock | 188,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-010287 · doc4.xml · nonDerivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 669,288 F1 · shares: The reporting person was granted restricted stock units, with each unit representing the right to receive one share of the issuer's common stock. These restricted stock units will vest in full on March 31, 2022. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 16:06 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionStock Option (right to buy) · Derivative | 12,084 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001179110-18-013361 · edgar.xml · derivative · entry 5 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 785,523 Underlying: Common Stock · 12,084 shares Expires 2024-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 16:06 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionStock Option (right to buy) · Derivative | 75,050 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001179110-18-013361 · edgar.xml · derivative · entry 4 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 797,607 Underlying: Common Stock · 75,050 shares Expires 2023-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 16:06 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionStock Option (right to buy) · Derivative | 23,454 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001179110-18-013361 · edgar.xml · derivative · entry 3 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 872,657 Underlying: Common Stock · 23,454 shares Expires 2023-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 16:06 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionCommon Stock | 12,084 | $3.04 | $36,735.36 |
DisclosureSEC source: 0001179110-18-013361 · edgar.xml · nonDerivative · entry 2 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 481,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 16:06 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionCommon Stock | 98,504 | $1.01 | $99,489.04 |
DisclosureSEC source: 0001179110-18-013361 · edgar.xml · nonDerivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2018 Filed May 22, 2018 20:10 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 9,260 | $0.00 Strike: $56.77 | $0.00 |
DisclosureSEC source: 0001203311-18-000037 · edgardoc.xml · derivative · entry 2 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,260 Underlying: Common Stock · 9,260 shares Expires 2028-05-18 F3 · derivative.exercise_date: The option shall vest in full on May 18, 2019. Read SEC document |
| May 18, 2018 Filed May 22, 2018 20:10 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 3,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001203311-18-000037 · edgardoc.xml · nonDerivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,800 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F2 · deemedExecutionDate: Restricted stock units shall vest in full on May 18, 2019. Read SEC document |
| May 08, 2018 Filed May 10, 2018 18:04 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option · Derivative | 31,380 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-18-012414 · doc4.xml · derivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,380 Underlying: Common Stock · 31,380 shares Expires 2028-05-08 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments following the award grant date. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 16:08 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 285,000 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0001179110-18-002463 · edgar.xml · derivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,000 Underlying: Common Stock · 285,000 shares Expires 2028-02-15 F1 · derivative.exercise_date: This option becomes exercisable as to 25% of the shares underlying the award on February 28, 2019, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award at the end of each successive month thereafter. Read SEC document |
| May 19, 2017 Filed May 23, 2017 19:22 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 9,260 | $0.00 Strike: $66.60 | $0.00 |
DisclosureSEC source: 0001203311-17-000024 · edgardoc.xml · derivative · entry 2 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,260 Underlying: Common Stock · 9,260 shares Expires 2027-05-18 F3 · derivative.exercise_date: The option shall vest in full on May 18, 2018. Read SEC document |
| May 19, 2017 Filed May 23, 2017 19:22 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 3,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001203311-17-000024 · edgardoc.xml · nonDerivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,100 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F2 · date: Restricted stock units shall vest in full on May 18, 2018. Read SEC document |
| February 10, 2017 Filed Feb 13, 2017 17:17 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001179110-17-002279 · edgar.xml · derivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2027-02-09 F1 · derivative.exercise_date: This option becomes exercisable as to 25% of the shares underlying the award on February 10, 2018, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award at the end of each successive month thereafter. Read SEC document |
| September 16, 2016 Filed Sep 19, 2016 06:59 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $12.17 | $0.00 |
DisclosureSEC source: 0001104659-16-145308 · a4.xml · derivative · entry 1 Simonian Nancy A · CIK 0001359574 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2026-09-15 F1 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares underlying the award on the one year anniversary of the award, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award until the fourth anniversary of the date of the award, subject to Dr. Simonian's continued service through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.